Summary
Introduction: Local delivery of adriamycin (ADR) via biodegradable polymers has been shown to improve survival in rats challenged intracranially with 9L gliosarcoma. Likewise, local delivery of interleukin-2 (IL-2) has been shown to extend survival in experimental brain tumor models. In the current study, we hypothesized that local delivery of ADR and IL-2 might act synergistically against experimental intracranial glioma.
Methods: Polyanhydride polymers (PCPP-SA) containing 5% ADR by weight were prepared using the mix-melt method. IL-2 polymer microspheres (IL-2 MS) were produced via the complex coacervation of gelatin and chondroitin sulfate in the presence of IL-2. Sixty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. In addition, a group of rats were injected with either IL-2 MS or empty microspheres. Five days later they received ADR or blank polymer. There were a total of four treatment groups: (1) empty microspheres, blank polymer; (2) empty microspheres, ADR polymer; (3) IL-2 MS, blank polymer; and (4) IL-2 MS, ADR polymer.
Results: Compared to control animals treated with empty microspheres and blank polymer, animals receiving empty microspheres and ADR polymer (P < 0.0004), IL-2 MS and blank polymer (P < 0.0005), and IL-2 MS combined with ADR polymer (P < 0.0000002) all showed statistically significant improvement in survival. In addition, animals receiving the IL-2/ADR combination had significantly extended survival compared to either ADR or IL-2 alone (P < 0.000003 and P < 0.0004, respectively).
Conclusions: Both ADR and IL-2, when delivered locally, are effective monotherapeutic agents against experimental intracranial gliosarcoma. The combination ADR and IL-2 therapy is more effective than either agent alone.
Similar content being viewed by others
References
H Brem et al. (1991) ArticleTitleInterstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas J Neurosurg 74 441–446 Occurrence Handle1993909
H Brem et al. (1995) ArticleTitlePlacebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 345 1008–1012 Occurrence Handle10.1016/S0140-6736(95)90755-6 Occurrence Handle7723496
S Valtonen et al. (1997) ArticleTitleInterstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study Neurosurgery 41 44–48 Occurrence Handle10.1097/00006123-199707000-00011 Occurrence Handle9218294
KA Walter RJ Tamargo A Olivi PC Burger H Brem (1995) ArticleTitleIntratumoral chemotherapy Neurosurgery 37 1128–1145 Occurrence Handle8584154
M Westphal et al. (2003) ArticleTitleA phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-oncol 5 79–88 Occurrence Handle10.1215/S1522851702000236 Occurrence Handle12672279
JE Wolff T Trilling G Molenkamp RM Egeler H Jurgens (1999) ArticleTitleChemosensitivity of glioma cells in vitro: a meta analysis J Cancer Res Clin Oncol 125 481–486 Occurrence Handle10.1007/s004320050305 Occurrence Handle10480340
T. Ohnishi et al. (1995) ArticleTitleIn vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier Biochem Pharmacol 49 1541–1544 Occurrence Handle10.1016/0006-2952(95)00082-B Occurrence Handle7763297
RJ Tushinksi (1991) Biology of cytokines: the interleukins VT Devita S Hellman SA Rosenberg (Eds) Biologic Therapy of Cancer J.B. Lippincott Company Philadelphia 87–94
DM Pardoll (1995) ArticleTitleParacrine cytokine adjuvants in cancer immunotherapy Annu Rev Immunol 13 399–415 Occurrence Handle10.1146/annurev.iy.13.040195.002151 Occurrence Handle7612229
ER Fearon et al. (1990) ArticleTitleInterleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 60 397–403 Occurrence Handle10.1016/0092-8674(90)90591-2 Occurrence Handle2137372
SA Rosenberg et al. (1989) ArticleTitleExperience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Ann Surg 210 474–484 Occurrence Handle2679456
T Lichtor RP Glick TS Kim R Hand EP Cohen (1995) ArticleTitleProlonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells J Neurosurg 83 1038–1044 Occurrence Handle7490618
RC Thompson et al. (1996) ArticleTitleSystemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors J Immunother Emphasis Tumor Immunol 19 405–413 Occurrence Handle9041459
RP Glick T Lichtor E Zoeten Particlede P Deshmukh EP Cohen (1999) ArticleTitleProlongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2 Neurosurgery 45 867–874 Occurrence Handle10.1097/00006123-199910000-00028 Occurrence Handle10515482
T Lichtor et al. (2002) ArticleTitleApplication of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors Cancer Gene Ther 9 464–469 Occurrence Handle10.1038/sj.cgt.7700459 Occurrence Handle11961669
J Hanes et al. (2001) ArticleTitleControlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors Pharm Res 18 899–906 Occurrence Handle10.1023/A:1010963307097 Occurrence Handle11496947
A Nigam et al. (1998) ArticleTitleImmunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines Int J Oncol 12 161–170 Occurrence Handle9454900
K Tsung JB Meko YL Tsung GR Peplinski JA Norton (1998) ArticleTitleImmune response against large tumors eradicated by treatment with cyclophosphamide and IL-12 J Immunol 160 1369–1377 Occurrence Handle9570556
P Sampath et al. (1999) ArticleTitleParacrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors Cancer Res 59 2107–2114 Occurrence Handle10232596
LD Rhines et al. (2003) ArticleTitleLocal immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma Neurosurgery 52 872–879 Occurrence Handle10.1227/01.NEU.0000053211.39087.D1 Occurrence Handle12657184
EP Sipos B Tyler S Piantadosi PC Burger H Brem (1997) ArticleTitleOptimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors Cancer Chemother Pharmacol 39 383–389 Occurrence Handle10.1007/s002800050588 Occurrence Handle9054951
A Olivi et al. (1996) ArticleTitleInterstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat Cancer Chemother Pharmacol 39 90–96
E Kaplan P Meier (1958) ArticleTitleNon-parametric estimation from incomplete observations J Am Stat Associ 53 457–481
N Mantel W Haenszel (1959) ArticleTitleStatistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 719–748 Occurrence Handle13655060
P Hau et al. (2004) ArticleTitlePegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma Cancer 100 1199–1207 Occurrence Handle10.1002/cncr.20073 Occurrence Handle15022287
SC Steiniger et al. (2004) ArticleTitleChemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles Int J Cancer 109 759–767 Occurrence Handle10.1002/ijc.20048 Occurrence Handle14999786
M Rittierodt K Harada (2003) ArticleTitleRepetitive doxorubicin treatment of glioblastoma enhances the PGP expression – a special role for endothelial cells Exp Toxicol Pathol 55 39–44 Occurrence Handle10.1078/0940-2993-00287 Occurrence Handle12940627
RP Glick T Lichtor TS Kim S Ilangovan EP Cohen (1995) ArticleTitleFibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo Neurosurgery 36 548–555 Occurrence Handle7753355
W Griffitt RP Glick T Lichtor EP Cohen (1998) ArticleTitleSurvival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system Neurosurgery 42 335–340 Occurrence Handle10.1097/00006123-199802000-00075 Occurrence Handle9482184
L Staib W Harel MS Mitchell (1993) ArticleTitleProtection against experimental cerebral metastases of murine melanoma B16 by active immunization Cancer Res 53 1113–1121 Occurrence Handle8439956
WF Hickey (1991) ArticleTitleMigration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation Brain Pathol 1 97–105 Occurrence Handle1669702
A Fontana H Hengartner N Tribolet Particlede E Weber (1984) ArticleTitleGlioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects J Immunol 132 1837–1844 Occurrence Handle6607949
SC Saris et al. (1992) ArticleTitleTreatment of murine primary brain tumors with␣systemic interleukin-2 and tumor-infiltrating lymphocytes J Neurosurg 76 513–519 Occurrence Handle1738033
A Akbasak EH Oldfield SC Saris (1991) ArticleTitleExpression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro J Neurosurg 75 922–992 Occurrence Handle1941122
F DiMeco et al. (2000) ArticleTitleParacrine delivery of IL-12 against intracranial 9L gliosarcoma in rats J Neurosurg 92 419–427 Occurrence Handle10701528
CE Weber (1998) ArticleTitleCytokine-modified tumor vaccines: an antitumor strategy revisited in the age of molecular medicine Cancer Nurs 21 167–177 Occurrence Handle10.1097/00002820-199806000-00003 Occurrence Handle9615507
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hsu, W., Lesniak, M.S., Tyler, B. et al. Local Delivery of Interleukin-2 and Adriamycin is Synergistic in the Treatment of Experimental Malignant Glioma. J Neurooncol 74, 135–140 (2005). https://doi.org/10.1007/s11060-004-6597-8
Issue Date:
DOI: https://doi.org/10.1007/s11060-004-6597-8